UBC’s School of Biomedical Engineering (SBME) invites LSBC members to propose a project for our Capstone Design Course, to be undertaken by 4th-year undergraduate student teams from Sept 2022-May 2023, by filling out this submission form by August 1st. Participating organizations have benefitted by promoting their organization to UBC students and researchers, working with potential future employees, as well as receiving custom solutions and prototypes for evaluation...READ MORE

InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly-owned subsidiary, BayMedica LLC...READ MORE

Introducing the Canada Gairdner Momentum Award! This award annually recognizes 2 mid-career investigators (typically 10-15 years past their first independent research appointment) working in Canada who in their last 6 active years have produced exceptional scientific research contributions with continued potential for impact on human health...READ MORE

Aspect Biosystems, a biotechnology company pioneering the development of bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of five new advisors to the Company’s Scientific Advisory Board. Appointments include Dr. James Shapiro, Dr. Anil Dhawan, Dr. Jane Lebkowski, Dr. Shinichiro Ogawa, and Dr. Omid Veiseh.“I am thrilled to welcome five experts who are at the top of their respective fields to Aspect’s Scientific Advisory Board,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems...READ MORE

Lab2Launch supports UBC researchers and scientists who plan to build, or are building, a deep tech venture based on a proprietary and novel scientific or technological innovation. Participants in this stream will dive deep into the DNA of their venture opportunity, articulating the problem they are solving, identifying who experiences this problem, and why the proposed solution is the preferred market opportunity...READ MORE

Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease. This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders...READ MORE

InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announced the closing of its previously announced registered direct offering and concurrent private placement with a single healthcare-focused institutional investor priced at-the-market under Nasdaq rules...READ MORE

Novartis announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients...READ MORE

Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients along with Inscripta®, a global leader in automated, CRISPR-based gene editing technology, announced that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows...READ MORE

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present on the development of its pancreatic tissue therapeutic program at the American Diabetes Association 82nd Scientific Sessions, held June 3-7, 2022 in New Orleans, LA and virtually...READ MORE

Genomic research is leading to incredible advances in modern-day healthcare but combining health and genomic data can greatly accelerate new discoveries. To enable the advancement of medical research and patient care, Genome British Columbia (Genome BC) has committed an investment of up to $1 million in partnership with Providence Health Care Ventures (Ventures)...READ MORE

Evonik, one of the world’s leading providers of drug delivery technologies, is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the United States. The new plant at Evonik’s Tippecanoe site in Lafayette, Indiana, will broadly position the Group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines and strengthen its leading role as a strategic partner for innovative pharmaceutical companies worldwide...READ MORE

The Creative Destruction Lab (CDL) is a nine-month early-stage program for science and technology-driven startups. The program takes no equity and charges no fees, and participating Ventures do not need to relocate. At the core of the program are five intensive, full-day summit meetings that happen every eight weeks, where founders meet a curated group of investors, successful tech entrepreneurs, and technologists to set short-term objectives and raise capital. Interested ventures can reach out directly to Kamal Bhandal <kamal.bhandal@creativedestructionlab.com>, Senior Venture Manager, with any questions they may have...READ MORE

Repare Therapeutics Inc. has struck a deal with pharmaceutical giant F. Hoffman-La Roche AG that could be worth more than US$1 billion. The Montreal-based cancer drug company, which is working on highly-targeted therapies, says Roche will help develop and commercialize the drug camonsertib...READ MORE

The Research and Innovation Manager is a collaborative member of the Research and Innovation team and works seamlessly across the organization. Reporting to the Senior Research and Innovation Manager you will work with the Research and Innovation leadership to implement the research and innovation mandate towards the strategic goals of the organization.

The Data and Document Specialist in Quality Control Department will work closely with a team of scientific staff and department management in preparing and managing documents in the department. Please note that this is a TEMP role for 12 months. Evonik offers excellent benefits such as competitive compensation, benefit & pension plans, vacation and time off, and many wellness resources.